Development of engineered pancreatic β-cell lines for cell therapy of diabetes

Research output: Contribution to journalReview articlepeer-review


Insulin-secreting pancreatic β-cell lines represent a promising approach for treatment of insulin-dependent diabetes mellitus (IDDM). Our laboratory has developed a number of highly-differentiated β-cell lines in transgenic mice. These cells produce insulin amounts comparable to normal pancreatic islets and release it in response to physiological insulin secretagogues. Using a reversible transformation system it has become possible to tightly regulate cell replication in these β-cell lines both in culture and in vivo. By employing adenovirus genes which downreguate antigen presentation and increase cell resistance to cytokines mouse β cells could be transplanted across allogeneic barriers. These approaches could be applied to the development of human β-cell lines by genetic engineering of isolated human islets. Copyright (C) 1998 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)45-52
Number of pages8
JournalAdvanced Drug Delivery Reviews
Issue number1-2
StatePublished - 3 Aug 1998
Externally publishedYes


  • Adenovirus E3 genes
  • Beta cells
  • Cell therapy
  • Diabetes
  • Insulin
  • Pancreatic islets
  • T antigen
  • Transgenic mice
  • Transplantation


Dive into the research topics of 'Development of engineered pancreatic β-cell lines for cell therapy of diabetes'. Together they form a unique fingerprint.

Cite this